Phaseline

Targets › FCRL5

FCRL5 (Fc receptor-like protein 5): drug programs, companies and trials

3 programs from 2 companies in 10 trials: 4 Phase 1, 3 Phase 3, 3 Phase 2; Oncology, Neurology, Immunology; next expected readout Nov 2026.

Plays an important role in B-cell response to antigen that acts both as a negative or positive coreceptor. Inhibits B-cell receptor (BCR) signaling in the absence of CR2 stimulation but engagement with CR2 and the BCR lead to a superior calcium response compared to CR2 and BCR costimulation. (UniProt, Q96RD9)

Open in Phaseline: the race on FCRL5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
argenxEmpasiprubart
FcRn antagonist
FCRN, FCRL5Phase 3Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor Neuropathy (MMN); Dermatomyositis; AChR-Ab Seropositive Generalized Myasthenia Gravis …Nov 2026
Xuzhou Medical Universityanti-FcRL5 CAR-T
anti-FcRL5 CAR-T cell therapy
FCRL5Phase 1Multiple MyelomaJan 2027
Xuzhou Medical Universityanti-BCMA/FcRL5 CAR-T
dual-targeted CAR-T cell therapy targeting BCMA and FcRL5
BCMA, FCRL5Phase 1Multiple MyelomaDec 2027

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy (2) Multifocal Motor Neuropathy (MMN) (2) AChR-Ab Seropositive Generalized Myasthenia Gravis (2) Multiple Myeloma (2) Dermatomyositis (1) Healthy Volunteers (1)

Modalities

other (2), antibody (1)

Companies

Xuzhou Medical University (2) argenx (1)

Related targets

FCRN (1) BCMA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.